Aclarion Announces Publication of Seminal Nociscan Cost-Effectiveness Analysis
Aclarion (NASDAQ: ACON) announced the publication of a peer-reviewed cost-effectiveness analysis of their Nociscan technology in Clinicoeconomics and Outcomes Research. The study demonstrates that Nociscan, a SaaS platform that helps identify chronic low back pain locations, is more cost-effective than traditional provocative discography.
The analysis reveals that Nociscan saves $1,712 per patient and improves surgical success rates by 10%. The technology uses biomarkers and AI algorithms to noninvasively help physicians distinguish between painful and nonpainful discs in the lumbar spine, addressing a global healthcare challenge affecting approximately 266 million people worldwide with degenerative spine disease and low back pain.
Aclarion (NASDAQ: ACON) ha annunciato la pubblicazione di un'analisi di costo-efficacia peer-reviewed della loro tecnologia Nociscan su Clinicoeconomics and Outcomes Research. Lo studio dimostra che Nociscan, una piattaforma SaaS che aiuta a identificare le aree di dolore cronico alla schiena, è più conveniente rispetto alla discografia provocativa tradizionale.
L'analisi evidenzia che Nociscan permette un risparmio di 1.712 dollari per paziente e migliora del 10% il tasso di successo chirurgico. La tecnologia utilizza biomarcatori e algoritmi di intelligenza artificiale per aiutare i medici a distinguere in modo non invasivo tra dischi dolorosi e non dolorosi nella colonna lombare, affrontando una sfida sanitaria globale che interessa circa 266 milioni di persone nel mondo affette da malattie degenerative della colonna e dolore lombare cronico.
Aclarion (NASDAQ: ACON) anunció la publicación de un análisis de costo-efectividad revisado por pares de su tecnología Nociscan en Clinicoeconomics and Outcomes Research. El estudio demuestra que Nociscan, una plataforma SaaS que ayuda a identificar las zonas de dolor crónico en la espalda baja, es más rentable que la discografía provocativa tradicional.
El análisis revela que Nociscan ahorra 1,712 dólares por paciente y mejora en un 10% las tasas de éxito quirúrgico. La tecnología utiliza biomarcadores y algoritmos de inteligencia artificial para ayudar de forma no invasiva a los médicos a distinguir entre discos dolorosos y no dolorosos en la columna lumbar, abordando un desafío sanitario global que afecta a aproximadamente 266 millones de personas en todo el mundo con enfermedad degenerativa de la columna y dolor lumbar.
Aclarion (NASDAQ: ACON)은(는) 동료 검토를 거친 비용 효율성 분석을 Nociscan 기술에 대해 Clinicoeconomics and Outcomes Research에 발표했다고 밝혔습니다. 이 연구는 만성 요통 부위를 식별하는 데 도움을 주는 SaaS 플랫폼인 Nociscan이 기존의 도발성 추간판 조영술보다 비용 효율적임을 보여줍니다.
분석 결과 Nociscan은 환자당 1,712달러를 절감하며 수술 성공률을 10% 향상시키는 것으로 나타났습니다. 이 기술은 생체표지자와 인공지능 알고리즘을 활용해 비침습적으로 요추의 통증이 있는 디스크와 없는 디스크를 구분하여 전 세계 약 2억 6,600만 명의 퇴행성 척추 질환 및 요통 환자들이 겪는 글로벌 의료 문제를 해결합니다.
Aclarion (NASDAQ : ACON) a annoncé la publication d'une analyse coût-efficacité évaluée par des pairs de leur technologie Nociscan dans Clinicoeconomics and Outcomes Research. L'étude démontre que Nociscan, une plateforme SaaS aidant à identifier les zones de douleur chronique au bas du dos, est plus rentable que la discographie provocatrice traditionnelle.
L'analyse révèle que Nociscan permet une économie de 1 712 $ par patient et améliore de 10 % les taux de réussite chirurgicale. Cette technologie utilise des biomarqueurs et des algorithmes d'IA pour aider les médecins, de manière non invasive, à distinguer les disques douloureux des disques non douloureux dans la colonne lombaire, répondant ainsi à un défi mondial de santé touchant environ 266 millions de personnes dans le monde souffrant de maladies dégénératives de la colonne vertébrale et de lombalgies.
Aclarion (NASDAQ: ACON) gab die Veröffentlichung einer von Fachkollegen begutachteten Kosten-Nutzen-Analyse ihrer Nociscan-Technologie in Clinicoeconomics and Outcomes Research bekannt. Die Studie zeigt, dass Nociscan, eine SaaS-Plattform zur Identifikation chronischer Rückenschmerzstellen, kosteneffektiver ist als die herkömmliche provokative Diskographie.
Die Analyse zeigt, dass Nociscan pro Patient 1.712 US-Dollar einspart und die chirurgischen Erfolgsraten um 10 % verbessert. Die Technologie nutzt Biomarker und KI-Algorithmen, um Ärzten nichtinvasiv zu helfen, schmerzhafte von schmerzfreien Bandscheiben in der Lendenwirbelsäule zu unterscheiden – ein globales Gesundheitsproblem, das weltweit etwa 266 Millionen Menschen mit degenerativen Wirbelsäulenerkrankungen und Rückenschmerzen betrifft.
- Cost savings of $1,712 per patient compared to traditional methods
- 10% improvement in surgical success rates
- Peer-reviewed validation of technology effectiveness
- Addresses large market of 266 million people with chronic low back pain
- None.
Insights
Aclarion's Nociscan diagnostic tool demonstrates superior cost-effectiveness compared to traditional methods, saving $1,712 per patient while improving surgical success by 10%.
The publication of this peer-reviewed cost-effectiveness analysis represents a significant validation milestone for Aclarion's Nociscan technology. The study, published in ClinicoEconomics and Outcomes Research, provides quantitative evidence that Nociscan outperforms provocative discography both clinically and economically in identifying chronic low back pain sources.
The demonstrated
The endorsement from Dr. Doug Beall, a radiology specialist, suggests potential for adoption across multiple specialties including surgery, pain management, and interventional radiology. For a diagnostic technology like Nociscan, which uses biomarkers and AI algorithms to non-invasively identify painful discs, this type of multi-disciplinary appeal could strengthen its clinical positioning.
The economic findings in this study present a compelling value proposition in today's cost-conscious healthcare environment. The specific cost savings of
This dual validation of both cost reduction and improved clinical outcomes creates exactly what healthcare systems operating under value-based care models seek: better outcomes at lower costs. Most diagnostic technologies struggle to demonstrate both simultaneously.
The explicit mention of payer relevance by Aclarion's Chief Strategy Officer highlights the strategic importance of this data for reimbursement discussions. Payers increasingly demand evidence of economic benefit alongside clinical efficacy before providing coverage for new technologies.
The non-invasive nature of Nociscan compared to provocative discography also represents a patient experience improvement that aligns with patient-centered care priorities. When diagnostic technologies can demonstrate this trifecta of economic savings, clinical improvement, and enhanced patient experience, they typically gain stronger consideration from healthcare decision-makers.
- Independent Cost-Effectiveness Analysis Concludes Nociscan is Effective and Less Costly Compared to Provocative Discography
- Conclusions Illustrate Nociscan Saves
$1,712 per Patient and Improves Surgical Success by10%
BROOMFIELD, Colo., April 21, 2025 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, announced today the publication of a peer-reviewed article in Clinicoeconomics and Outcomes Research titled "The Comparison of Cost-Effectiveness Between Magnetic Resonance Spectroscopy and Provocative Discography in the Identification of Chronic Low Back Pain Surgery Candidates.”
“Chronic low back pain is a complex problem that is complicated to diagnose,” said Doug Beall, MD, Chief of Radiology Services, Clinical Radiology of Oklahoma and co-author. “I have a keen interest in advanced diagnostics and clinical decision support tools like Nociscan. The profound conclusions within this important paper will not only benefit surgical intervention, but also my non-surgical colleagues in Pain Management and Interventional Radiology. Our industry needs more evidence showcasing clinical and economic improvements when comparing alternatives, and our paper clearly illustrates the cost-effectiveness of Nociscan compared to provocative discography.”
ClinicoEconomics and Outcomes Research is a peer-reviewed healthcare journal focusing on covering the economic impact of health policy and health systems organization. The journal was established in 2009 and is published by Dove Medical Press.
“We are pleased with the cost-effectiveness results illustrated in this important paper,” said Ryan Bond, Chief Strategy Officer at Aclarion. “We believe the results demonstrating Nociscan’s economic outperformance over provocative discography will be important to our physician customers and their patients, but will also speak clearly to the payer community, who are constantly challenged to reconcile the health outcomes achieved for the dollars they spend, in other words, the value in healthcare.”
Chronic low back pain (cLBP) is a global healthcare problem with approximately 266 million people worldwide suffering from degenerative spine disease and low back pain. Aclarion’s Nociscan solution is the first evidence-supported SaaS platform to noninvasively help physicians distinguish between painful and nonpainful discs in the lumbar spine. Nociscan objectively quantifies chemical biomarkers demonstrated to be associated with disc pain. When used with other diagnostic tools, Nociscan provides critical insights into the location of a patient’s low back pain.
To find a Nociscan center, view our site map here.
For more information on Nociscan, please email: info@aclarion.com
All organizations cited and/or quotes from individuals not part of Aclarion have reviewed and approved the contents herein.
About Aclarion, Inc.
Aclarion is a healthcare technology company that leverages Magnetic Resonance Spectroscopy (“MRS”), proprietary signal processing techniques, biomarkers, and augmented intelligence algorithms to optimize clinical treatments. The Company is first addressing the chronic low back pain market with Nociscan, the first, evidence-supported, SaaS platform to noninvasively help physicians distinguish between painful and nonpainful discs in the lumbar spine. Through a cloud connection, Nociscan receives magnetic resonance spectroscopy (MRS) data from an MRI machine for each lumbar disc being evaluated. In the cloud, proprietary signal processing techniques extract and quantify chemical biomarkers demonstrated to be associated with disc pain. Biomarker data is entered into proprietary algorithms to indicate if a disc may be a source of pain. When used with other diagnostic tools, Nociscan provides critical insights into the location of a patient’s low back pain, giving physicians clarity to optimize treatment strategies. For more information, please visit www.aclarion.com.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 about the Company’s current expectations about future results, performance, prospects and opportunities. Statements that are not historical facts, such as “anticipates,” “believes” and “expects” or similar expressions, are forward-looking statements. These forward-looking statements are based on the current plans and expectations of management and are subject to a number of uncertainties and risks that could significantly affect the Company’s current plans and expectations, as well as future results of operations and financial condition. These and other risks and uncertainties are discussed more fully in our filings with the Securities and Exchange Commission. Readers are encouraged to review the section titled “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024, as well as other disclosures contained in the Prospectus and subsequent filings made with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date and the Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Investor Contacts:
Kirin M. Smith
PCG Advisory, Inc.
ksmith@pcgadvisory.com
Media Contact:
Jennie Kim
SPRIG Consulting
jennie@sprigconsulting.com
FAQ
How much cost savings does Aclarion's Nociscan provide compared to provocative discography?
What is the improvement in surgical success rate with Nociscan (ACON)?
How does Aclarion's Nociscan technology identify chronic low back pain?
Where was Aclarion's Nociscan cost-effectiveness study published?
